Stock 603351 NANJING WELL PHARMACEUTICAL GROUP CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Nanjing Well Pharmaceutical Group Co.,Ltd. Stock

Equities

603351

CNE100003JD4

Oil & Gas Refining and Marketing

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
23.3 CNY +0.82% Intraday chart for Nanjing Well Pharmaceutical Group Co.,Ltd. -2.96% -11.64%
Apr. 25 Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
2023 Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI

Financials

Sales 2022 1.11B 153M Sales 2023 1.16B 160M Capitalization 3.57B 493M
Net income 2022 95M 13.12M Net income 2023 112M 15.47M EV / Sales 2022 2.93 x
Net Debt 2022 325M 44.9M Net Debt 2023 328M 45.32M EV / Sales 2023 3.37 x
P/E ratio 2022
30.5 x
P/E ratio 2023
31.8 x
Employees 673
Yield 2022
1.29%
Yield 2023
1.14%
Free-Float 37.11%
More Fundamentals * Assessed data

Chart Nanjing Well Pharmaceutical Group Co.,Ltd.

Dynamic Chart

Latest news about Nanjing Well Pharmaceutical Group Co.,Ltd.

Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Nanjing Well Pharmaceutical Group Co.,Ltd. completed the acquisition of13% stake in Nanjing Xingwei Biotechnology Co., Ltd. from Wu Renrong, Gao Zhengsong, Chen Xinguo, Tang Qunsong, Shen Jiusi, Wu Rongwen, Hong Shilin, Zou Jianguo, Wang Fuqiu and Zhou Chong. CI
Nanjing Well Pharmaceutical Group Co.,Ltd. signed an agreement to acquire 13% stake in Nanjing Xingwei Biotechnology Co., Ltd. from Wu Renrong, Gao Zhengsong, Chen Xinguo, Tang Qunsong, Shen Jiusi, Wu Rongwen, Hong Shilin, Zou Jianguo, Wang Fuqiu and Zhou Chong for CNY0. CI
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Certain A Shares of Nanjing Well Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 30-JAN-2022. CI
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
More news

Quotes and Performance

1 day+0.82%
1 week-2.96%
1 month-5.59%
3 months+10.37%
6 months-15.33%
Current year-11.64%
More quotes

Highs and lows

1 week
22.99
Extreme 22.99
24.39
1 month
22.99
Extreme 22.99
26.44
Current year
17.65
Extreme 17.65
26.96
1 year
17.65
Extreme 17.65
29.80
3 years
17.08
Extreme 17.08
42.62
5 years
17.08
Extreme 17.08
42.62
10 years
17.08
Extreme 17.08
42.62
More quotes

Managers and Directors - Nanjing Well Pharmaceutical Group Co.,Ltd.

Managers TitleAgeSince
Ren Rong Wu CEO
 Chief Executive Officer 61 00-01-31
Qun Song Tang DFI
 Director of Finance/CFO 56 00-01-31
Rong Wen Wu CHM
 Chairman 58 00-07-31
Members of the board TitleAgeSince
Ya Mei Guan BRD
 Director/Board Member 54 23-05-17
Ren Rong Wu CEO
 Chief Executive Officer 61 00-01-31
Zheng Song Gao CTO
 Chief Tech/Sci/R&D Officer 58 00-01-31
More insiders

Quotes

Date Price Change Volume
24-05-31 23.3 +0.82% 286,500
24-05-30 23.11 -1.66% 380,600
24-05-29 23.5 -0.55% 477,960
24-05-28 23.63 -0.30% 328,500
24-05-27 23.7 -1.29% 735,600

End-of-day quote Shanghai S.E., May 30, 2024

More quotes

Company Profile

Nanjing Well Pharmaceutical Group Co Ltd, formerly Nanjing Well Pharmaceutical Co Ltd, is a China-based company principally involved in the research and development, manufacturing and sales of pharmaceutical auxiliary materials and synthetic lubricating base oil products. Its main products include pharmaceutical auxiliary materials, synthetic lubricating base oil and pesticide additives. The Company distributes its products primarily in domestic market.
Sector
Oil & Gas Refining and Marketing
Calendar
2024-08-19 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Sector Other Oil & Gas Refining and Marketing

1st Jan change Capi.
NANJING WELL PHARMACEUTICAL GROUP CO.,LTD. Stock Nanjing Well Pharmaceutical Group Co.,Ltd.
-11.64% 436M
RELIANCE INDUSTRIES LTD Stock Reliance Industries Ltd
+10.67% 232B
CHINA PETROLEUM & CHEMICAL CORPORATION Stock China Petroleum & Chemical Corporation
+21.27% 102B
BP PLC Stock BP PLC
+4.72% 102B
MARATHON PETROLEUM CORPORATION Stock Marathon Petroleum Corporation
+19.04% 62.23B
PHILLIPS 66 Stock Phillips 66
+6.74% 60.25B
VALERO ENERGY CORPORATION Stock Valero Energy Corporation
+20.88% 51.38B
IMPERIAL OIL LIMITED Stock Imperial Oil Limited
+27.58% 37.82B
INDIAN OIL CORPORATION LIMITED Stock Indian Oil Corporation Limited
+25.07% 26.8B
REPSOL S.A. Stock Repsol S.A.
+11.67% 19.82B
Other Oil & Gas Refining and Marketing
  1. Stock Market
  2. Equities
  3. 603351 Stock